Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non-endemic Chikungunya Region
Sponsor: Defense Advanced Research Projects Agency
A PHASE1 clinical study on Chikungunya Virus, this trial is completed. The trial is conducted by Defense Advanced Research Projects Agency and has accumulated 10 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Defense Advanced Research Projects Agency
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .